Session Details

Session Details

08:00 AM - 09:45 AM - Room 339-342

Eva Andres-Mateos - PhD - Atsena Therapeutics

Co-Chair

08:00 AM - 09:45 AM - Room 339-342

Julia Davydova - PhD, MD - UMN

Co-Chair

08:00 AM - 08:15 AM - Room 339-342

Pieter Lindenbergh - Memorial Sloan Kettering Cancer Center

233: CAR T-Cell-Derived TNF Drives Cytokine Release Syndrome and Enhances M1 Macrophage Differentiation

08:15 AM - 08:30 AM - Room 339-342

Supreet Khanal - PhD - FDA

234: Identification of Cellular Factors that Contribute to Peripheral Blood-Derived CAR-NK Cell Mediated Inflammatory Toxicities

08:30 AM - 08:45 AM - Room 339-342

Elaine Youngman - Interius BioTherapeutics

235: Pharmacokinetics and Vector Shedding in NHPs Following a Single Intravenous Infusion of a CD20-Targeted Engineered Lentiviral Vector

08:45 AM - 09:00 AM - Room 339-342

Margarita Romanenko - PhD - University of Minnesota

236: Characterization of Preclinical Models for Systemically Delivered Vectors Based on Human Adenoviruses HAdV-B3, HAdV-B11, HAdV-C5, HAdV-C6, and HAdV-D26

09:00 AM - 09:15 AM - Room 339-342

Utku Goreke - PhD - Innovative Genomics Institute, University of California Berkeley

237: Potency Assay Enabling Both Ex Vivo and In Vivo Genome Editing Therapeutics for Sickle Cell Disease

09:15 AM - 09:30 AM - Room 339-342

Ilya Shestopalov - PhD - bluebird bio

238: Association Between Potency Critical Quality Attributes and Clinical Efficacy Across Lentiviral Vector Cell and Gene Therapy Products

09:30 AM - 09:45 AM - Room 339-342

Fumiaki Aihara - Novartis

239: Transcriptional Changes in Non-Human Primate Tissues After Intrathecal Delivery of Serotype 9 Adeno-Associated Viral Vector: Insights into Organ Toxicities